ARCHIVES

Cancer Drugs Initiatives To Shorten approval Times, Ensure Post-Marketing Studies, FDA Official Says

This article is from The Cancer Letter archive.

Vol. 22 No. 17 | April 26, 1996

Download PDF Visit The Full Archive

Related Articles

NCAB Members Skeptical On NCI Reorganization; King Has “Alterative;” Terry T Head Centers

January 27, 1978

Dingell Asks FDA To Explain Failure To Curtail ESA Ads.

June 15, 2007

MM-121 Study Fails PFS Endpoint, Biomarker Analysis Continues

November 29, 2013

Prostate Cancer: NIH Pans To Ramp Up Prostate Cancer Research Funding

June 25, 1999

Local Labs Not As Accurate As Central Testing For HER2

August 30, 2002

Colonoscopy Every Three Years Indicated For Those With Family History Of Polyps

May 31, 2002